Revenues at Vertex's Irish unit rose to $2.3bn last year Sales of the ground breaking Cystic Fibrosis drug, KAFTRIO, was the main driver behind Vertex Pharmaceutical's Irish revenues surging to $2.3bn last year. Business • 22 Aug 24
Revenues at Vertex's Irish unit rose to $2.3bn last year Sales of the ground breaking Cystic Fibrosis drug, KAFTRIO, was the main driver behind Vertex Pharmaceutical's Irish revenues surging to $2.3bn last year. Business • 22 Aug 24
Cystic fibrosis drug sales drive Vertex revenues higher Sales of the ground breaking cystic fibrosis drug KAFTRIO was the main driver behind Vertex Pharmaceutical's revenues surging to $1.955 billion (€1.79 billion) last year. Business • 03 Jul 23
Cystic fibrosis drug sales drive Vertex revenues higher Sales of the ground breaking cystic fibrosis drug KAFTRIO was the main driver behind Vertex Pharmaceutical's revenues surging to $1.955 billion (€1.79 billion) last year. Business • 03 Jul 23
